ライフサイエンスコーパス: EIA

1 EIA determined leukotriene B4, and ELISAs quantified TNF

2 EIA stenoses were significantly longer in women (P < .00

3 Upon hip flexion, 23 CIA and 116 EIA stenoses showed kinking (mean amplitude, 76 degrees

4 red testing (MTTT) algorithms, including a 2-EIA algorithm and modified criteria for second-tier IgG

5 e data add to the mounting evidence that a 2-EIA-based MTTT algorithm, where immunoblotting is replac

6 The 2-EIA MTTT algorithm slightly enhanced sensitivity in earl

7 In addition, the MTTT algorithm utilizing 2-EIAs was found to be equivalent to all STTT algorithms t

8 the 1996 group as compared to 34.3% in 2011 (EIA, P < 0.001).

9 y mortality was 13% in 2222 adults with 2745 EIA-positive samples (median, 78 years) vs 5% in 20,722

10 VISP, with 94.3% testing reactive with all 3 EIA kits tested.

11 78 years) vs 5% in 20,722 adults with 27,550 EIA-negative samples (median, 74 years) (absolute attrib

12 Most (71.6%) EIA-positive samples were positive by PCR for C. jejuni/

13 d CIN3+ was assessed relative to the GP5+/6+ EIA results by using noninferiority criteria.

14 n of electromagnetically induced absorption (EIA) through near-field coupling in these systems has on

15 denovirus promoter and suppresses adenovirus EIA gene expression, which is a master regulator of aden

16 in the US Energy Information Administration (EIA)'s Annual Energy Outlook (AEO), for investment and p

17 The highly specific and sensitive HCV-Ags EIA developed in the present study has the lowest limit

18 ondenaturation of serum samples, our HCV-Ags EIA reliably differentiated V-HCV infection from resolve

19 d, using sample nondenaturation, the HCV-Ags EIA results showed 98.9% specificity and 100% sensitivit

20 HCV infection and developed a novel HCV-Ags EIA through simultaneous detection of all four HCV prote

21 he lowest limits of detection of the HCV-Ags EIA were equivalent to serum HCV RNA levels of approxima

22 vel HCV antigens enzyme immunoassay (HCV-Ags EIA) and assessed its sensitivity, specificity, and util

23 The high proportion of SRA positivity among EIA-seroconverting patients (8/11 [73%]) suggests that p

24 bacter jejuni, and Campylobacter coli and an EIA for Shiga toxins 1 and 2.

25 Verification studies of an EIA compared to culture revealed a positive predictive v

26 Given that the primary purpose of an EIA is to make planning decisions evidence-based, our re

27 d (n = 1,667/116,188 [1.4%]; P < 0.001), and EIA was more sensitive than O&P.

28 s than unexposed nonpatients (P = .023), and EIA results were significantly lower among case patients

29 USA-06 titer < 8 (55% vs 14%; P = .033), and EIA index standard ratio < 1.40 (64% vs 9%; P = .002) an

30 Combining antigen and EIA antibody testing provides an optimal method for diag

31 They were mild (CIA and EIA mean severity, 19% +/- 7 and 26% +/- 11, respectivel

32 CIA and EIA stenoses predominantly involved the distal and proxi

33 ere identified by both SMAC agar culture and EIA, 6 (9%) by SMAC agar culture alone, and 2 (3%) by EI

34 Based on these data, culture and EIA-based methods for detection of STEC are only 33% sen

35 G)E(2) production were measured by ELISA and EIA.

36 The LMNX and EIA were in high agreement (Cohen's kappa = 0.969) for t

37 small heterodimer partner (SHP, NR0B2), and EIA-like inhibitor of differentiation 1 (EID1) in choles

38 re positive among patients with both O&P and EIA performed (2.5%) than among those with O&P only perf

39 compared with cases detected by both PCR and EIA/CCA (3% vs 39%, respectively; P < .001).

40 The incidence rate ratio comparing PCR and EIA/CCA was 1.52 (95% CI, 1.08-2.13; P = .015).

41 om different clades/sequence types (STs) and EIA-negative controls using Cox and normal regression ad

42 The MVista Histoplasma antibody EIA offers increased sensitivity over current antibody t

43 controls in the MVista Histoplasma antibody EIA.

44 noassay and cell culture cytotoxicity assay (EIA/CCA).

45 e HSK lesions by enzyme immunosorbent assay (EIA) and confocal microscopy.

46 ch required Environmental Impact Assessment (EIA) for certain types of industrial and infrastructure

47 Environmental Impact Assessments (EIAs) are the main tool used across the world to predict

48 A new VRD B19V IgG avidity EIA showed good (>95%) agreement (excluding equivocal re

49 The concordance between EIA and IFA findings was 96.7%.

50 for antibodies to measles virus and HIV-1 by EIA.

51 %) by SMAC agar culture alone, and 2 (3%) by EIA alone.

52 per 10 000 patient-days (95% CI, 4.4-7.4) by EIA/CCA (P = .01).

53 CDI was diagnosed by PCR and 39% (22/56) by EIA/CCA (P = .16).

54 C1-INH functional activity was assessed by EIA.

55 Detection of stool toxin A and/or B by EIA does not predict severe CDI or mortality.

56 I cases were detected by PCR and 56 cases by EIA/CCA (P = .01).

57 Patients with a positive result for IgM by EIA are thought to have a diagnosis of acute coccidioido

58 The presence of stool toxin measured by EIA does not correlate with disease severity.

59 26.5, and 50% of the GII samples negative by EIA had a C(T) of >25.6, suggesting that, although strai

60 Most GII samples positive by EIA had a threshold cycle (C(T)) of <26.5, and 50% of th

61 orally inoculated aged pig were positive by EIA, IHC, and/or WB.

62 gative-continue to test strongly positive by EIA-IgG.

63 associated specimens were toxin positive by EIA.

64 d two-dose recipients reported previously by EIA was shown to be smaller by PRN.

65 t react with hMPV IgG-positive human sera by EIA.

66 t and halt the practice of serial testing by EIA.

67 We performed a C6 EIA on all collected specimens, followed by a supplement

68 approach where the second-tier test was a C6 EIA.

69 ence, expressed (VlsE) CLIA followed by a C6 EIA.

70 ole-cell sonicate (WCS) EIA followed by a C6 EIA; (2) a WCS EIA followed by a VlsE chemiluminescence

71 We then compared the performance of the C6 EIA alone and as a first-tier test followed by immunoblo

72 The C6 EIA alone had sensitivity similar to that of standard 2-

73 dergoing evaluation for Lyme disease, the C6 EIA could guide initial clinical decision making, althou

74 However, the C6 EIA has not been extensively studied in pediatric patien

75 lowed by a supplemental immunoblot if the C6 EIA result was positive but the whole-cell sonicate EIA

76 mmunoblot improved the specificity of the C6 EIA to 98.6%.

77 , where immunoblotting is replaced by the C6 EIA, performs as well or better than STTT.

78 re with three EIA methods, the Premier CAMPY EIA (Meridian Bioscience, Cincinnati, OH), the ProSpecT

79 Cincinnati, OH), the ProSpecT Campylobacter EIA (Remel, Lenexa, KS), and the ImmunoCard STAT!

80 the Premier CAMPY and ProSpecT Campylobacter EIAs were 99.3% and 98%, respectively, while the ImmunoC

81 toxins A and B by Wampole Tox A/B Quik Chek EIA (AB-Q), performed sequentially.

82 ydrogenase (GDH) by Wampole C Diff Quik Chek EIA (GDH-Q) and negative for toxins A and B by Wampole T

83 otech, Oakville, Ontario, Canada], Trep-Chek EIA [Phoenix Biotech], Trep-ID EIA [Phoenix Biotech], an

84 We conclude that the developed Chip EIA can be used for detection of protein biomarkers in b

85 A power-free, portable "Chip EIA" was designed to render the popular Enzyme Linked Im

86 The lower detection limit of the PSA Chip EIA was 3.2 ng/mL.

87 The PSA Chip EIA was tested for accuracy, precision, repeatability, a

88 The Chip EIA device was used to assay total prostate specific ant

89 The Chip EIA platform has eliminated the need for pumps and valve

90 CIA, EIA, and femoral lesions were not randomly associated (P

91 The CIA, EIA, and femoral lesion classification may help to disti

92 We compared culture for C. jejuni/C. coli, EIA (ProSpecT), and duplex PCR to distinguish Campylobac

93 e 4th-generation Murex HIV Ag/Ab Combination EIA (enzyme immunoassay) within an adolescent and young-

94 xclude toxigenic C. difficile, and combining EIAs with CYT in a three-step algorithm failed to substa

95 By competition EIA, no cross-reactivity between the BuVs was detected,

96 nd 5.7% (n = 9,754) included Cryptosporidium EIA.

97 were evaluated, including stool EIA, culture EIA, and real-time PCR (tcdA and tcdB) of cultured isola

98 tivity superior to that of stool and culture EIAs and performance comparable to that of real-time PCR

99 microbiological methods, including culture, EIA, and reverse-transcriptase PCR.

100 In conclusion, the current EIA may be of use as a rapid screening test during a nor

101 The GP5+/6+-PCR EIA (EIA) was used as a comparator assay and showed sensitivi

102 drogenase (GDH) screening followed by either EIA or EIA and an in-house PCR assay.

103 ulture and more rapid turnaround than either EIA or culture.

104 V-specific IgG and IgM, IgG avidity, and ETS EIAs.

105 19.25%) O&P examinations, 47/204 (23.04%) GC-EIA, and 249/1,229 (20.26%) STCUL were ordered after 3 d

106 (8.83%) O&P examinations, 27/157 (17.20%) GC-EIA, and 106/1,028 (10.31%) STCUL were ordered after 3 d

107 O&P examinations (P < 0.0001), 22.58% for GC-EIA (P = 0.2807), and 49.1% for STCUL (P < 0.0001).

108 yptosporidium enzyme immunoassay screens (GC-EIA) performed for patients hospitalized >3 days.

109 gorithm in which DPCR is used to analyze GDH EIA-positive, toxin EIA-negative specimens provides a co

110 0.001 by Fisher's exact test) and to the GDH-EIA-CCCN algorithm (P, 0.0363).

111 The GDH-EIA-CCCN procedure required, on average, 2 days to compl

112 with sensitivity similar to third-generation EIAs.

113 One MAb had broad cross-genogroup EIA reactivity to a nonblockade, linear, conserved epito

114 ded O&P, 27.9% (n = 47,666) included Giardia EIA, and 5.7% (n = 9,754) included Cryptosporidium EIA.

115 HBV antibodies and GM-EIA positivity are common in patients receiving IVIG and

116 rm in the following three stages: (i) DS2 GM-EIA method validation with experimental samples, (ii) DS

117 amples, and (iii) a 12-month audit of DS2 GM-EIA performance.

118 a reduction in false-positive (equivocal) GM-EIA results, reducing the need to retest a significant p

119 Certain IVIG products tested positive for GM-EIA and there were rises in index values in correspondin

120 samples post-infusion tested positive for GM-EIA.

121 sion of galactomannan enzyme immunoassay (GM-EIA) (2002) and beta-d-glucan (2008), providing a minima

122 The galactomannan enzyme immunoassay (GM-EIA) is widely utilized for the diagnosis of invasive as

123 nces in galactomannan enzyme immunoassay (GM-EIA) performance have been reported and are attributed t

124 ies and galactomannan enzyme immunoassay (GM-EIA) positivity.

125 least equivalent to that used to include GM-EIA and beta-d-glucan testing, and that PCR is now matur

126 When incorporated, GM-EIA and beta-d-glucan sensitivities and specificities fo

127 ); and pre- and post-infusion analysis of GM-EIA in 37 patients receiving IVIG.

128 ing therapy such as rituximab; a positive GM-EIA result prompts investigation or treatment for invasi

129 This study demonstrates that GM-EIA automation may reduce intersite variability.

130 dy investigated the semiautomation of the GM-EIA on the DS2 (Dynex) platform in the following three s

131 We detected, by in-house EIA, BuV1-3 IgG antibodies in 7/228 children (3.1%) and

132 a], Trep-Chek EIA [Phoenix Biotech], Trep-ID EIA [Phoenix Biotech], and Treponema ViraBlot IgG [Viram

133 EIA to 98.4% (96.1 to 99.4) for the Trep-ID EIA.

134 9V IgM positive by a commercial VRD B19V IgM EIA and B19V IgM negative by a new HI in-house B19V VP2

135 Both VRD B19V qPCR and HI B19V VP2 IgM EIA gave the highest agreement with consensus interpreta

136 M negative by a new HI in-house B19V VP2 IgM EIA.

137 s of the common iliac (CIA), external iliac (EIA), and femoral arteries were classified into five typ

138 sted for Shiga toxins by enzyme immunoassay (EIA) (ImmunoCard STAT! enterohemorrhagic E. coli [EHEC];

139 G) level was measured by enzyme immunoassay (EIA) and by plaque reduction neutralization (PRN) on a s

140 We compared paired enzyme immunoassay (EIA) and latex agglutination (LA) assay results with 185

141 their antigenicities by enzyme immunoassay (EIA) and surrogate antibody neutralization (blockade) as

142 sly with the GP5+/6+ PCR enzyme immunoassay (EIA) and the GP5+/6+ PCR LMNX assay (Diassay) were teste

143 or C. difficile by toxin enzyme immunoassay (EIA) and toxigenic culture (TC).

144 for the more established enzyme immunoassay (EIA) detection of 14 targeted high-risk human papillomav

145 or Lyme disease (LD), an enzyme immunoassay (EIA) followed by immunoglobulin M and immunoglobulin G W

146 key (SMAC) agar culture, enzyme immunoassay (EIA) for Shiga toxin, or the simultaneous use of both me

147 Enzyme immunoassay (EIA) for toxins A/B is too insensitive for use as a stan

148 cially-available C6 Lyme enzyme immunoassay (EIA) has been approved to replace the standard whole-cel

149 Administration-approved enzyme immunoassay (EIA) HIV antibody kits were used to determine VISP, and

150 cially available heparin enzyme immunoassay (EIA) kit that has a limit of detection of approximately

151 Antibody detection by enzyme immunoassay (EIA) may increase sensitivity and permit the measurement

152 for toxins A and/or B by enzyme immunoassay (EIA) or tcdB by polymerase chain reaction.

153 ter antigen detection by enzyme immunoassay (EIA) provides rapid results compared to traditional cult

154 tions of a Campylobacter enzyme immunoassay (EIA) result and the increasing importance of molecular t

155 m routine culture and an enzyme immunoassay (EIA) specific for the recovery and identification of STE

156 number of false-positive enzyme immunoassay (EIA) test results for IgM among persons suspected of hav

157 ctive Treponema pallidum enzyme immunoassay (EIA) tests.

158 nd a competitive magneto-enzyme immunoassay (EIA) that enables high sensitivity.

159 rst tier is typically an enzyme immunoassay (EIA) that if positive or equivocal is reflexed to Wester

160 unofluorescence assay or enzyme immunoassay (EIA) that, if the result is positive or equivocal, is fo

161 ibodies were measured by enzyme immunoassay (EIA) with confirmation by immunofluorescence or recombin

162 s, a less-sensitive (LS) enzyme immunoassay (EIA), and the BED assay.

163 xiom Diagnostics HEV IgG enzyme immunoassay (EIA), and the Mikrogen recomLine HEV IgG assay.

164 ydrogenase and toxin A/B enzyme immunoassay (EIA), and the RTCA assay.

165 n (GM) in urine using an enzyme immunoassay (EIA), and we showed low positive agreement (64.5%) with

166 test is a serodiagnostic enzyme immunoassay (EIA), containing p6 and gp41 peptides, designed to diffe

167 The methods included enzyme immunoassay (EIA), direct cytotoxin testing, and two- and three-step

168 ologic tests, such as an enzyme immunoassay (EIA), followed by Western blot testing, to diagnose extr

169 ng (WB), antigen capture enzyme immunoassay (EIA), immunohistochemistry (IHC), and in vitro real-time

170 ted in stool by culture, enzyme immunoassay (EIA), or PCR.

171 PF4/heparin IgG-specific enzyme immunoassay (EIA), testing serial serum samples in a patient with rec

172 ) assay, a toxin A and B enzyme immunoassay (EIA), the Xpert C. difficile assay, and a cell culture c

173 ure antibody include the enzyme immunoassay (EIA), which measures immunoglobulin G (IgG) to all measl

174 stridium difficile toxin enzyme immunoassay (EIA)-positive fecal samples from Oxfordshire, United Kin

175 body to hRSV and hMPV by enzyme immunoassay (EIA).

176 e verified by a standard enzyme immunoassay (EIA).

177 sted for EBV antibody by enzyme immunoassay (EIA).

178 rus Iowa-G/USA-06 and by enzyme immunoassay (EIA).

179 test (SCT), the GP5+/6+ enzyme immunoassay (EIA).

180 rformed using an HEV IgG enzyme immunoassay (EIA, Axiom Diagnostics), and the recomLine HEV IgG immun

181 telia Aspergillus enzyme-linked immunoassay (EIA), due to contamination with galactomannan (GM).

182 Malvern, PA], Trep-Sure enzyme immunoassay [EIA; Phoenix Biotech, Oakville, Ontario, Canada], Trep-C

183 iscordant results (e.g., enzyme immunoassay [EIA] reactive and reactive plasma reagin [RPR] nonreacti

184 DEIA Norovirus assay (an enzyme immunoassay [EIA]) in a prospective and retrospective study design.

185 -release assay [SRA] and enzyme-immunoassay [EIA]), and the frequency of recurrent HIT in 20 patients

186 ransitioning from toxin enzyme immunoassays (EIA) to nucleic acid amplification tests (NAATs) as the

187 rgely replaced by rapid enzyme immunoassays (EIA).

188 Currently, culture and enzyme immunoassays (EIAs) are the primary methods used by clinical laborator

189 type specificity (ETS) enzyme immunoassays (EIAs) for distinguishing past from recent infection.

190 commercially available enzyme immunoassays (EIAs) have been developed for the direct detection of C.

191 hysician use of O&P and enzyme immunoassays (EIAs) with the yield of parasites detected.

192 espectively, vs 7.0 x 10(9) neutrophils/L in EIA-negative controls (P < .0001) and 7.9 x 10(9) neutro

193 ents with a positive TC but a negative index EIA developed CDI within 30 days after the index test or

194 Intraoperative heparin induced EIA seroconversion in 11/17 (65%) patients (immunoglobul

195 efines HIV positive), 84% and 73% for the LS-EIA (</=0.2 cutoff), 88% and 72% for the BED (</=0.2 cut

196 he Bio-Rad WB (0.90); within 60 days, the LS-EIA and BED (both 0.85); and for persons within 90 days

197 Overall, the LYM/LYG EIAs performed equivalently to the LYT EIA in test-to-te

198 The dissociated LYM/LYG EIAs were evaluated against the combined LYT EIA using s

199 the Vidas Lyme IgM II (LYM) and IgG II (LYG) EIAs, which use purified recombinant test antigens and a

200 EIAs were evaluated against the combined LYT EIA using samples from 471 well-characterized Lyme patie

201 M/LYG EIAs performed equivalently to the LYT EIA in test-to-test comparisons or as first-tier assays

202 reactivity, defined as reactive on 1 or more EIA tests and either Western blot-negative or Western bl

203 tive IMMY GM ASR results and positive MVista EIA results, testing was performed for initial diagnosti

204 The MVista EIA results were positive for 6/12 samples that tested i

205 es for one patient (<0.4 ng/ml by the MVista EIA) and UAg levels were being monitored for the remaini

206 g two patients (both<0.7 ng/ml by the MVista EIA).

207 (135/150 samples) with respect to the MVista EIA.

208 es were tested with both the IMMY and MVista EIAs, and clinical histories were recorded for all study

209 tients with an IgM-positive and IgG-negative EIA result did not have coccidioidomycosis.

210 A classical analog of EIA opens up opportunities for designing novel photonic

211 Performing PCR instead of EIA/CCA is associated with a >50% increase in the CDI in

212 , respectively, compared with the results of EIA and 8.7% and 98.0%, respectively, compared with the

213 associated with an increased sensitivity of EIA (P = 0.31).

214 In a subset of EIA+/VDRL-/TP-PA+ cases, 48% were previously treated.

215 Automation of EIAs can reduce variation.

216 e (HI), Helsinki, Finland, using a number of EIAs, e.g., B19V-specific IgG and IgM, IgG avidity, and

217 ation of qPCR or by appropriate selection of EIAs.

218 >1 assay, are more expensive than the older EIA assays; however, rapid and accurate testing can save

219 ere positive) and compared to culture and/or EIA for archival specimens (42 of 85 specimens were posi

220 Compared to culture or EIA, the positive percent agreement (PPA) and negative p

221 se (GDH) screening followed by either EIA or EIA and an in-house PCR assay.

222 physicians also preferentially used O&P over EIA, but no Cryptosporidium cases were detected by O&P.

223 Serum analysis using an oxytocin EIA kit indicated a significant up-regulation of the bio

224 ve value were 56%, 100%, 100%, and 90% for P-EIA and 81%, 100%, 100%, and 96% for both algorithm 1 an

225 ifficile toxin A and B enzyme immunoassay [P-EIA]).

226 ions with superior sensitivity compared to P-EIA.

227 The GP5+/6+-PCR EIA (EIA) was used as a comparator assay and showed sens

228 etric microtiter PCR enzyme immunoassay (PCR-EIA) used as a diagnostic assay.

229 In comparison to the PCR-EIA, PCR/ESI-MS possessed a sensitivity, a specificity,

230 CSF was most highly predictive of a positive EIA result.

231 ith low pretest probabilities had a positive EIA, but four were TC positive.

232 We suggest all positive EIA results be confirmed via culture.

233 in developing country settings, the ProSpecT EIA and PCR for Campylobacter reveal extremely high rate

234 Vista) Histoplasma antigen (Ag) quantitative EIA (MiraVista Diagnostics, Indianapolis, IN).

235 ed [40.9%]) occurred with the HIV 1/2 (rDNA) EIA kit compared with the rLAV EIA (150/700 tested [21.4

236 cycles: 69.7%) versus 73 patients receiving EIA alone (>/=5 cycles: 52.1%, P=0.027).

237 ovement to develop a formal legal/regulatory EIA process for large industrial and infrastructure proj

238 IV 1/2 (rDNA) EIA kit compared with the rLAV EIA (150/700 tested [21.4%]), HIV-1 Plus O Microelisa Sy

239 to replace the standard whole-cell sonicate EIA as a first-tier test for the diagnosis of Lyme disea

240 ult was positive but the whole-cell sonicate EIA result was negative.

241 Standard EIAs, Western blots, and HIV incidence assays provide us

242 on were: 34%-57% and 98%-100% for 2 standard EIAs (employing a signal-to-cutoff </=4.0; >/=1.0 define

243 nsitivities of stool real-time PCR and stool EIA were 95% and 35%, respectively, with a specificity o

244 g modalities were evaluated, including stool EIA, culture EIA, and real-time PCR (tcdA and tcdB) of c

245 ver, due to the lack of sensitivity of stool EIA, we developed a multiplex real-time PCR assay target

246 The Advia-Centaur CIA and Trep-Sure EIA had signal strength cutoffs correlating with at leas

247 ged from 86.3% (84.1 to 88.2%) for Trep-Sure EIA to 100% for TP-PA (99.6 to 100%).

248 ce interval, 92.3 to 97.3) for the Trep-Sure EIA to 98.4% (96.1 to 99.4) for the Trep-ID EIA.

249 ssay [CIA], Advia-Centaur CIA, and Trep-Sure EIA) and three manual assays (Treponema pallidum particl

250 demonstrate that PCR is more sensitive than EIA and/or culture and distinguishes between O157 and no

251 ns evidence-based, our results indicate that EIA mitigation strategies used to date have been ineffec

252 Given that EIAs are undertaken globally, are extremely expensive, a

253 The EIA missed 18.4% detected by the LA assay in the blood s

254 The EIA was able to detect strains from 7 GI and 11 GII geno

255 An algorithm using the GDH assay and the EIA (plus the CCCN if the EIA was negative) showed corre

256 th the immunogenicity of the vaccine and the EIA assay used.

257 GDH assay and the EIA (plus the CCCN if the EIA was negative) showed corresponding values of 83.1, 9

258 IA (27 stenoses, one dissection), 185 in the EIA (17 thromboses, 167 stenoses, one dissection), one i

259 Here we present the observation of the EIA analog due to constructive interference in a vertica

260 ere not detected, the low sensitivity of the EIA is primarily caused by low virus concentration.

261 The analytical sensitivity of the EIA was 3.1 x 10(6) and 1.6 x 10(7) virus particles g(-1

262 The sensitivity of the EIA was significantly lower than that of the Xpert C. di

263 The sensitivity and specificity of the EIA were 57.6% and 91.9%, respectively.

264 mproved sensitivity of the LA assay over the EIA in non-HIV patients.

265 87.5% (28 of 32), which was higher than the EIA result (P = 0.005) but lower than the PCR result (P

266 cile assay was statistically superior to the EIA (P, <0.001 by Fisher's exact test) and to the GDH-EI

267 ults, we consider the LMNX, similarly to the EIA, useful for HPV-based cervical cancer screening.

268 V) of 94.4, 96.3, 84.0, and 98.8%, while the EIA alone gave corresponding values of 58.3, 94.7, 68.9,

269 The overall sensitivity of the EIAs compared to that of enrichment culture was 60.0%, a

270 l platelet activation assays even when their EIAs remain strongly positive.

271 conducted to assess the performance of these EIAs as first-tier tests and when used in two-tiered alg

272 udy compared conventional culture with three EIA methods, the Premier CAMPY EIA (Meridian Bioscience,

273 These results showed that the three EIAs evaluated in this study provide a rapid and reliabl

274 res one of the most commonly used first-tier EIAs in the United States, the combined IgM/IgG Vidas te

275 100% sensitivity and specificity compared to EIA and culture for specimens collected prospectively (4

276 inimally affected by strain type compared to EIA and GDH-based methods.

277 100% sensitivity and specificity compared to EIA and/or culture and more rapid turnaround than either

278 ith severe CDI, 58% tested positive by toxin EIA and 98% tested positive by NAAT.

279 with mild CDI, 49% tested positive by toxin EIA and 98% tested positive by NAAT.

280 n for CDI were tested prospectively by toxin EIA, by C. difficile NAAT, and with a reference standard

281 or died within 90 days after the index toxin EIA date.

282 Neither CYT nor toxin EIA was sufficiently sensitive to exclude toxigenic C. d

283 R is used to analyze GDH EIA-positive, toxin EIA-negative specimens provides a convenient and specifi

284 hod and a Shiga toxin EIA, but a Shiga toxin EIA should not be considered to be an adequate stand-alo

285 se of an agar-based method and a Shiga toxin EIA, but a Shiga toxin EIA should not be considered to b

286 These data demonstrate that toxin EIA performs poorly both for patients with severe CDI an

287 that the analytical sensitivity of the toxin EIA is poor, there are limited clinical data on the perf

288 The toxin EIA was positive in 37.2% and 35.6% of patients were of

289 ghlights the poor performance of stool toxin EIAs in pediatric settings.

290 s of 97% and 98 to 99% resulted when the two EIA strategies were followed by Western immunoblotting a

291 ukotriene and ECP levels were measured using EIAs or ELISAs.

292 te (WCS) EIA followed by a C6 EIA; (2) a WCS EIA followed by a VlsE chemiluminescence immunoassay (CL

293 ols included (1) a whole-cell sonicate (WCS) EIA followed by a C6 EIA; (2) a WCS EIA followed by a Vl

294 Here we assess how well EIAs of wind-farm developments protect bats.

295 les from nine were TC positive and four were EIA positive.

296 More episodes were positive when EIA was performed (n = 1,860/54,483 [3.4%]) than when O&

297 geminal ganglial neurons was quantified with EIA.

298 mpylobacter species revealed reactivity with EIA.

299 Seventy-six patients were treated with EIA (etoposide, ifosfamide, doxorubicin)+RHT (>/=5 cycle

300 ses diarrhoea attributable to rotavirus with EIAs or polyacrylamide gel electrophoresis.